Assessment of Liver Cancer Burden from 1990 to 2021 with Projections for 2040: Findings from the 2021 Global Burden of Disease Study - Report - MDSpire

Assessment of Liver Cancer Burden from 1990 to 2021 with Projections for 2040: Findings from the 2021 Global Burden of Disease Study

  • By

  • Yong Xie

  • Tianshi Lyu

  • Haitao Guan

  • Li Song

  • Xiaoqiang Tong

  • Yinghua Zou

  • Min Yang

  • Jian Wang

  • April 29, 2026

  • 0 min

Share

Clinical Report: Assessment of Liver Cancer Burden from 1990 to 2021

Overview

This study evaluates the global burden of liver cancer from 1990 to 2021, revealing significant increases in incidence and mortality, particularly related to hepatitis B virus (HBV). Projections indicate a continued rise in liver cancer cases through 2040, necessitating urgent public health interventions.

Background

Liver cancer poses a major public health challenge globally, with diverse etiologies including viral infections and metabolic syndromes. Understanding its burden is crucial for developing effective prevention and treatment strategies. The increasing incidence, particularly in older populations, highlights the need for targeted healthcare interventions.

Data Highlights

{'incidence': 'Include age-standardized rates for all liver cancer types.', 'deaths': 'Clarify the death rates with age-standardized metrics.'}

Key Findings

{'sociodemographic_indices': 'Add references to specific data supporting the correlation.'}

Clinical Implications

{'screening': 'Detail specific screening methods and preventive measures.'}

Conclusion

{'interventions': 'Suggest specific interdisciplinary approaches to tackle liver cancer burden.'}

References

  1. The ASCO Post, 2025 -- Three in Five Liver Cancer Cases May Be Due to Preventable Risk Factors
  2. The ASCO Post, 2025 -- Cancer Deaths Expected to Rise to Over 18 Million in 2050
  3. Open Forum Infectious Diseases, 2021 -- Mortality Rates Associated with Chronic Liver Diseases Due to Hepatitis B and C Infections in African Nations
  4. The ASCO Post — GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths
  5. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
  6. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma
  7. G L O B O C A N 2 0 2 2

Original Source(s)

Related Content